1. Home
  2. SUPN vs GDV Comparison

SUPN vs GDV Comparison

Compare SUPN & GDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • GDV
  • Stock Information
  • Founded
  • SUPN 2005
  • GDV 2003
  • Country
  • SUPN United States
  • GDV United States
  • Employees
  • SUPN N/A
  • GDV N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • GDV Investment Managers
  • Sector
  • SUPN Health Care
  • GDV Finance
  • Exchange
  • SUPN Nasdaq
  • GDV Nasdaq
  • Market Cap
  • SUPN 1.9B
  • GDV 2.0B
  • IPO Year
  • SUPN 2012
  • GDV N/A
  • Fundamental
  • Price
  • SUPN $32.28
  • GDV $24.85
  • Analyst Decision
  • SUPN Hold
  • GDV
  • Analyst Count
  • SUPN 2
  • GDV 0
  • Target Price
  • SUPN $36.00
  • GDV N/A
  • AVG Volume (30 Days)
  • SUPN 529.3K
  • GDV 186.0K
  • Earning Date
  • SUPN 08-05-2025
  • GDV 01-01-0001
  • Dividend Yield
  • SUPN N/A
  • GDV 5.81%
  • EPS Growth
  • SUPN N/A
  • GDV N/A
  • EPS
  • SUPN 1.11
  • GDV N/A
  • Revenue
  • SUPN $667,997,000.00
  • GDV N/A
  • Revenue This Year
  • SUPN N/A
  • GDV N/A
  • Revenue Next Year
  • SUPN $12.02
  • GDV N/A
  • P/E Ratio
  • SUPN $29.32
  • GDV N/A
  • Revenue Growth
  • SUPN 11.82
  • GDV N/A
  • 52 Week Low
  • SUPN $25.55
  • GDV $18.04
  • 52 Week High
  • SUPN $40.28
  • GDV $23.00
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 48.28
  • GDV 52.91
  • Support Level
  • SUPN $31.56
  • GDV $24.90
  • Resistance Level
  • SUPN $33.15
  • GDV $25.29
  • Average True Range (ATR)
  • SUPN 0.92
  • GDV 0.28
  • MACD
  • SUPN -0.03
  • GDV -0.07
  • Stochastic Oscillator
  • SUPN 40.34
  • GDV 31.71

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About GDV Gabelli Dividend & Income Trust of Beneficial Interest

Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, in which Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services and others.

Share on Social Networks: